Anticoagulation is ubiquitous in critical care. Considering the use of DVT prophylaxis, the majority of critically ill patients will receive some form of anticoagulation during their ICU stay. Anticoagulants are potentially high-risk medications, with relatively narrow therapeutic windows. Thus, it's important to understand the pharmacology of various agents to select and monitor anticoagulation optimally.
-
The IBCC chapter is located here.
- The podcast & comments are below.
Follow us on iTunes
The Podcast Episode
Want to Download the Episode?
Right Click Here and Choose Save-As
- Pulmcrit wee: The cutoff razor - April 15, 2024
- PulmCrit Blogitorial – Use of ECGs for management of (sub)massive PE - March 24, 2024
- PulmCrit Wee: Propofol induced eyelid opening apraxia – the struggle is real - March 20, 2024
I’m interested in pre-hospitalization treatment including dabigatran or another DOAC, at least at a low dose. One knock is possible drug interaction with an antiviral, but there doesn’t seem to be much enthusiasm for antivirals anyway. Could a DOAC and an interferon be used together?
Concerning the hospitalized, I wonder if your thinking tracks with this document from Emory: https://www.emoryhealthcare.org/ui/pdfs/covid/medical-professionals/COVID%20Emory%20VTE%20Guidelines%20FINAL.pdf
Hey guys, thanks for this amazing post and podcast. Im a great fan of your content. I have a question concerning the use of subcutaneous NMH in hemodynamically instable patients. In my unit it’s common practice to change NMH s.c. to UFH i.v. Once a certain threshold of Noradrenaline-Dosage is reached, with the underlying theory, that pharmakokinetics for s.c. application become unpredictable due to reduced perfusion of subcutaneous fat tissue. I kind of disagree with that practice because in my knowledge there is no evidentiary basis for it and NMH seem to generally be better and actually more predictable then… Read more »